| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Disease, Chronic Obstructive | 54 | 2024 | 164 | 12.920 |
Why?
|
| Lung | 47 | 2024 | 484 | 6.160 |
Why?
|
| Respiratory Mucosa | 24 | 2021 | 41 | 5.040 |
Why?
|
| Smoking | 36 | 2024 | 1019 | 5.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 18 | 2023 | 152 | 4.840 |
Why?
|
| Smoke | 18 | 2022 | 41 | 4.600 |
Why?
|
| Epithelial Cells | 28 | 2025 | 426 | 4.580 |
Why?
|
| Pulmonary Emphysema | 10 | 2024 | 13 | 3.180 |
Why?
|
| Bronchitis, Chronic | 6 | 2023 | 16 | 3.150 |
Why?
|
| Pneumonia | 10 | 2023 | 60 | 2.960 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2017 | 206 | 2.760 |
Why?
|
| Forced Expiratory Volume | 19 | 2024 | 75 | 2.700 |
Why?
|
| Mitochondrial Proteins | 8 | 2023 | 112 | 2.200 |
Why?
|
| Lipopolysaccharides | 15 | 2018 | 235 | 2.050 |
Why?
|
| Apoptosis Regulatory Proteins | 12 | 2025 | 160 | 1.880 |
Why?
|
| Asthma | 15 | 2022 | 410 | 1.880 |
Why?
|
| Respiratory Syncytial Virus Infections | 4 | 2022 | 16 | 1.880 |
Why?
|
| Health Status | 5 | 2018 | 432 | 1.820 |
Why?
|
| Emphysema | 3 | 2024 | 6 | 1.820 |
Why?
|
| Allergens | 13 | 2021 | 64 | 1.800 |
Why?
|
| Hyperplasia | 13 | 2021 | 39 | 1.730 |
Why?
|
| Animals | 84 | 2025 | 16695 | 1.700 |
Why?
|
| Wood | 8 | 2022 | 16 | 1.690 |
Why?
|
| Inflammation | 15 | 2023 | 729 | 1.630 |
Why?
|
| Mice, Inbred C57BL | 28 | 2025 | 1804 | 1.600 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2022 | 233 | 1.560 |
Why?
|
| Mice | 51 | 2025 | 6490 | 1.540 |
Why?
|
| Interleukin-13 | 5 | 2018 | 20 | 1.490 |
Why?
|
| Air Pollutants | 6 | 2022 | 127 | 1.480 |
Why?
|
| Apoptosis | 21 | 2023 | 1541 | 1.480 |
Why?
|
| Membrane Proteins | 10 | 2025 | 548 | 1.480 |
Why?
|
| Humans | 111 | 2025 | 42163 | 1.470 |
Why?
|
| Interferon-gamma | 10 | 2018 | 268 | 1.460 |
Why?
|
| Goblet Cells | 7 | 2016 | 12 | 1.400 |
Why?
|
| Bronchi | 12 | 2021 | 45 | 1.360 |
Why?
|
| Sputum | 6 | 2021 | 22 | 1.350 |
Why?
|
| Orthomyxoviridae Infections | 5 | 2025 | 14 | 1.330 |
Why?
|
| Influenza A virus | 4 | 2025 | 31 | 1.240 |
Why?
|
| Autophagy | 4 | 2013 | 136 | 1.230 |
Why?
|
| Bronchoalveolar Lavage Fluid | 19 | 2018 | 54 | 1.190 |
Why?
|
| Male | 70 | 2024 | 22779 | 1.160 |
Why?
|
| DNA Methylation | 9 | 2020 | 393 | 1.160 |
Why?
|
| Lung Neoplasms | 8 | 2020 | 479 | 1.150 |
Why?
|
| Hypersensitivity | 3 | 2018 | 32 | 1.120 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2025 | 115 | 1.080 |
Why?
|
| Mucus | 8 | 2016 | 15 | 1.070 |
Why?
|
| Spirometry | 6 | 2023 | 40 | 1.050 |
Why?
|
| Gene Expression | 9 | 2022 | 692 | 1.040 |
Why?
|
| Volatile Organic Compounds | 2 | 2022 | 20 | 0.960 |
Why?
|
| Metaplasia | 14 | 2016 | 39 | 0.950 |
Why?
|
| Pneumonia, Viral | 2 | 2018 | 86 | 0.950 |
Why?
|
| Middle Aged | 40 | 2024 | 11819 | 0.940 |
Why?
|
| Female | 61 | 2024 | 24018 | 0.920 |
Why?
|
| bcl-2-Associated X Protein | 5 | 2008 | 76 | 0.910 |
Why?
|
| Uteroglobin | 5 | 2018 | 9 | 0.900 |
Why?
|
| Aged | 34 | 2024 | 7982 | 0.880 |
Why?
|
| Proteomics | 4 | 2024 | 363 | 0.870 |
Why?
|
| Influenza, Human | 3 | 2025 | 90 | 0.860 |
Why?
|
| Hexosyltransferases | 1 | 2023 | 5 | 0.850 |
Why?
|
| Quality of Life | 3 | 2022 | 599 | 0.820 |
Why?
|
| Vital Capacity | 7 | 2024 | 44 | 0.810 |
Why?
|
| Cytokines | 11 | 2023 | 661 | 0.810 |
Why?
|
| Disease Models, Animal | 17 | 2024 | 1554 | 0.810 |
Why?
|
| Weight Gain | 2 | 2014 | 138 | 0.790 |
Why?
|
| Mucin 5AC | 6 | 2018 | 6 | 0.790 |
Why?
|
| Endoplasmic Reticulum | 2 | 2017 | 108 | 0.770 |
Why?
|
| Particulate Matter | 2 | 2022 | 80 | 0.770 |
Why?
|
| Mice, Knockout | 16 | 2020 | 1010 | 0.770 |
Why?
|
| Protein Processing, Post-Translational | 3 | 2013 | 184 | 0.770 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2022 | 8 | 0.750 |
Why?
|
| Airway Remodeling | 3 | 2018 | 11 | 0.750 |
Why?
|
| Mucins | 5 | 2022 | 69 | 0.740 |
Why?
|
| Neutrophils | 8 | 2019 | 141 | 0.730 |
Why?
|
| Casein Kinase II | 1 | 2021 | 16 | 0.730 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2012 | 81 | 0.730 |
Why?
|
| Mucous Membrane | 5 | 2011 | 34 | 0.710 |
Why?
|
| Risk Factors | 19 | 2025 | 3942 | 0.700 |
Why?
|
| Pyroglyphidae | 2 | 2018 | 4 | 0.680 |
Why?
|
| Endothelial Cells | 1 | 2023 | 324 | 0.660 |
Why?
|
| Homeostasis | 2 | 2020 | 193 | 0.660 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2024 | 49 | 0.660 |
Why?
|
| Gene Expression Regulation | 6 | 2019 | 1066 | 0.660 |
Why?
|
| Lysosomes | 1 | 2020 | 88 | 0.640 |
Why?
|
| Sequence Analysis, RNA | 2 | 2020 | 114 | 0.640 |
Why?
|
| Promoter Regions, Genetic | 7 | 2015 | 534 | 0.640 |
Why?
|
| Genes, bcl-2 | 4 | 2011 | 7 | 0.630 |
Why?
|
| Matrix Metalloproteinase 9 | 4 | 2019 | 95 | 0.630 |
Why?
|
| Tobacco Smoke Pollution | 5 | 2021 | 54 | 0.600 |
Why?
|
| Polymorphism, Single Nucleotide | 11 | 2025 | 860 | 0.590 |
Why?
|
| Adult | 29 | 2024 | 13458 | 0.580 |
Why?
|
| Rats, Inbred F344 | 10 | 2016 | 256 | 0.580 |
Why?
|
| New Mexico | 7 | 2018 | 36 | 0.570 |
Why?
|
| Cell Death | 5 | 2016 | 277 | 0.570 |
Why?
|
| Cough | 1 | 2018 | 20 | 0.570 |
Why?
|
| Interleukin-17 | 1 | 2018 | 53 | 0.570 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 12 | 0.570 |
Why?
|
| Nasal Septum | 1 | 2018 | 4 | 0.570 |
Why?
|
| Respiratory Syncytial Viruses | 2 | 2016 | 7 | 0.560 |
Why?
|
| Interleukin-9 | 2 | 2008 | 6 | 0.560 |
Why?
|
| Genome-Wide Association Study | 9 | 2023 | 421 | 0.560 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 136 | 0.560 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2017 | 4 | 0.560 |
Why?
|
| Ovalbumin | 9 | 2017 | 47 | 0.550 |
Why?
|
| RNA | 1 | 2020 | 266 | 0.550 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2006 | 255 | 0.550 |
Why?
|
| Mitochondria | 2 | 2020 | 516 | 0.540 |
Why?
|
| GATA4 Transcription Factor | 2 | 2014 | 6 | 0.530 |
Why?
|
| Caspase 3 | 3 | 2016 | 226 | 0.520 |
Why?
|
| Rats | 17 | 2018 | 3701 | 0.520 |
Why?
|
| Immunologic Memory | 1 | 2016 | 41 | 0.510 |
Why?
|
| Poly I-C | 1 | 2016 | 7 | 0.510 |
Why?
|
| Immunity, Mucosal | 1 | 2016 | 52 | 0.500 |
Why?
|
| Cells, Cultured | 10 | 2020 | 1617 | 0.500 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 3 | 2016 | 103 | 0.490 |
Why?
|
| RNA, Messenger | 6 | 2021 | 1265 | 0.490 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2016 | 100 | 0.490 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2019 | 727 | 0.480 |
Why?
|
| Cohort Studies | 11 | 2024 | 1729 | 0.480 |
Why?
|
| Time Factors | 7 | 2016 | 1848 | 0.480 |
Why?
|
| Obesity | 2 | 2014 | 1131 | 0.470 |
Why?
|
| Lung Diseases | 2 | 2014 | 62 | 0.460 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2014 | 16 | 0.450 |
Why?
|
| Cross-Sectional Studies | 8 | 2024 | 3077 | 0.450 |
Why?
|
| Genes, p53 | 1 | 2014 | 28 | 0.450 |
Why?
|
| Calcium | 1 | 2017 | 487 | 0.450 |
Why?
|
| Viral Proteins | 1 | 2016 | 196 | 0.440 |
Why?
|
| Environmental Exposure | 3 | 2018 | 247 | 0.430 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 378 | 0.420 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 78 | 0.420 |
Why?
|
| Disease Progression | 6 | 2021 | 661 | 0.420 |
Why?
|
| ADAM Proteins | 3 | 2020 | 20 | 0.420 |
Why?
|
| Neutrophil Infiltration | 3 | 2016 | 28 | 0.420 |
Why?
|
| Anoikis | 1 | 2013 | 21 | 0.420 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 638 | 0.420 |
Why?
|
| Trachea | 4 | 2017 | 25 | 0.400 |
Why?
|
| Air Pollution | 2 | 2005 | 87 | 0.390 |
Why?
|
| Inflammation Mediators | 5 | 2016 | 138 | 0.390 |
Why?
|
| Cell Division | 5 | 2021 | 314 | 0.380 |
Why?
|
| Severity of Illness Index | 5 | 2018 | 708 | 0.370 |
Why?
|
| Rolipram | 1 | 2011 | 2 | 0.360 |
Why?
|
| Respiratory Tract Diseases | 2 | 2024 | 30 | 0.350 |
Why?
|
| Macrophages, Alveolar | 6 | 2020 | 33 | 0.350 |
Why?
|
| Cell Nucleus | 2 | 2013 | 383 | 0.340 |
Why?
|
| Health Status Disparities | 2 | 2017 | 705 | 0.340 |
Why?
|
| Logistic Models | 5 | 2018 | 1001 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2016 | 184 | 0.330 |
Why?
|
| Mortality | 2 | 2024 | 174 | 0.330 |
Why?
|
| Interleukin-18 | 2 | 2007 | 16 | 0.320 |
Why?
|
| Cystic Fibrosis | 2 | 2012 | 27 | 0.320 |
Why?
|
| STAT1 Transcription Factor | 2 | 2007 | 35 | 0.310 |
Why?
|
| Respiratory Function Tests | 7 | 2024 | 61 | 0.310 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2008 | 6 | 0.300 |
Why?
|
| Respiratory Mechanics | 1 | 2008 | 27 | 0.300 |
Why?
|
| Phenotype | 8 | 2019 | 774 | 0.290 |
Why?
|
| Case-Control Studies | 8 | 2020 | 1266 | 0.290 |
Why?
|
| Respiratory Hypersensitivity | 2 | 2005 | 15 | 0.290 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2014 | 933 | 0.280 |
Why?
|
| Carbon Monoxide | 3 | 2022 | 48 | 0.280 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 287 | 0.270 |
Why?
|
| Matrix Metalloproteinase 8 | 2 | 2019 | 5 | 0.260 |
Why?
|
| Organ Culture Techniques | 3 | 2018 | 102 | 0.260 |
Why?
|
| Comorbidity | 3 | 2018 | 725 | 0.260 |
Why?
|
| Inhalation Exposure | 6 | 2018 | 44 | 0.250 |
Why?
|
| Airway Obstruction | 1 | 2006 | 9 | 0.250 |
Why?
|
| Horse Diseases | 1 | 2006 | 11 | 0.250 |
Why?
|
| Bronchial Hyperreactivity | 4 | 2013 | 12 | 0.240 |
Why?
|
| Antigens, CD | 2 | 2018 | 122 | 0.240 |
Why?
|
| Signal Transduction | 7 | 2020 | 2111 | 0.230 |
Why?
|
| Pulmonary Alveoli | 4 | 2021 | 27 | 0.230 |
Why?
|
| Cell Count | 4 | 2015 | 140 | 0.230 |
Why?
|
| Virus Replication | 4 | 2025 | 318 | 0.230 |
Why?
|
| Epigenesis, Genetic | 3 | 2020 | 274 | 0.230 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 40 | 0.230 |
Why?
|
| Nasal Mucosa | 1 | 2004 | 31 | 0.230 |
Why?
|
| Endothelium, Corneal | 1 | 2024 | 8 | 0.220 |
Why?
|
| Rats, Inbred BN | 5 | 2008 | 21 | 0.220 |
Why?
|
| Respiratory Tract Infections | 1 | 2024 | 36 | 0.220 |
Why?
|
| Linear Models | 2 | 2016 | 311 | 0.220 |
Why?
|
| Longitudinal Studies | 3 | 2024 | 1020 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2020 | 181 | 0.210 |
Why?
|
| Matrix Metalloproteinase 12 | 2 | 2016 | 4 | 0.210 |
Why?
|
| Proteins | 2 | 2003 | 383 | 0.200 |
Why?
|
| Chemokines | 3 | 2015 | 97 | 0.200 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2015 | 99 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2011 | 1112 | 0.200 |
Why?
|
| Sugar Alcohols | 1 | 2022 | 3 | 0.200 |
Why?
|
| Carbohydrates | 1 | 2022 | 32 | 0.190 |
Why?
|
| NF-kappa B | 4 | 2023 | 355 | 0.190 |
Why?
|
| Exocrine Glands | 1 | 2002 | 4 | 0.190 |
Why?
|
| Antiporters | 1 | 2022 | 13 | 0.190 |
Why?
|
| Dyspnea | 1 | 2022 | 23 | 0.190 |
Why?
|
| Odds Ratio | 3 | 2022 | 587 | 0.190 |
Why?
|
| Enzyme Activation | 2 | 2016 | 462 | 0.180 |
Why?
|
| Genotype | 5 | 2015 | 796 | 0.180 |
Why?
|
| Gene Silencing | 2 | 2013 | 154 | 0.180 |
Why?
|
| Interleukin-6 | 2 | 2002 | 165 | 0.180 |
Why?
|
| Matrix Metalloproteinase 1 | 2 | 2019 | 26 | 0.180 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 330 | 0.180 |
Why?
|
| Protective Agents | 1 | 2021 | 26 | 0.180 |
Why?
|
| GTPase-Activating Proteins | 1 | 2021 | 29 | 0.180 |
Why?
|
| Lung Injury | 1 | 2021 | 18 | 0.170 |
Why?
|
| Transcription Factors | 2 | 2022 | 722 | 0.170 |
Why?
|
| Pulmonary Fibrosis | 2 | 2019 | 38 | 0.170 |
Why?
|
| Metformin | 1 | 2021 | 74 | 0.170 |
Why?
|
| Species Specificity | 2 | 2015 | 279 | 0.160 |
Why?
|
| Genetic Loci | 2 | 2019 | 102 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2020 | 10 | 0.160 |
Why?
|
| Mice, Nude | 2 | 2016 | 403 | 0.160 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2020 | 12 | 0.160 |
Why?
|
| Ubiquitination | 2 | 2018 | 60 | 0.160 |
Why?
|
| Stem Cells | 1 | 2021 | 151 | 0.160 |
Why?
|
| Sphingolipids | 1 | 2020 | 14 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 310 | 0.160 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 2598 | 0.160 |
Why?
|
| Chronic Disease | 2 | 2014 | 541 | 0.160 |
Why?
|
| Prevalence | 2 | 2022 | 1597 | 0.160 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2019 | 16 | 0.150 |
Why?
|
| Markov Chains | 2 | 2016 | 42 | 0.150 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 438 | 0.150 |
Why?
|
| United States | 5 | 2023 | 5072 | 0.150 |
Why?
|
| Metabolomics | 1 | 2019 | 90 | 0.150 |
Why?
|
| Behavior, Animal | 1 | 2001 | 369 | 0.150 |
Why?
|
| Th2 Cells | 3 | 2008 | 63 | 0.150 |
Why?
|
| Pancreatic Elastase | 1 | 2018 | 7 | 0.150 |
Why?
|
| Energy Metabolism | 1 | 2019 | 181 | 0.140 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2013 | 44 | 0.140 |
Why?
|
| Infant | 1 | 2022 | 1143 | 0.140 |
Why?
|
| Antigens, Dermatophagoides | 1 | 2018 | 7 | 0.140 |
Why?
|
| Hospitalization | 1 | 2022 | 482 | 0.140 |
Why?
|
| Lymphocytes | 2 | 2016 | 124 | 0.140 |
Why?
|
| Aerosols | 3 | 2011 | 53 | 0.140 |
Why?
|
| Gases | 1 | 2018 | 25 | 0.140 |
Why?
|
| Sex Characteristics | 2 | 2015 | 253 | 0.140 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2017 | 14 | 0.140 |
Why?
|
| Mice, Inbred C3H | 2 | 2015 | 80 | 0.140 |
Why?
|
| Health Status Indicators | 2 | 2018 | 90 | 0.140 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 649 | 0.140 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 36 | 0.140 |
Why?
|
| Cardiovascular Diseases | 1 | 2024 | 729 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2015 | 95 | 0.140 |
Why?
|
| Aniline Compounds | 1 | 2017 | 27 | 0.130 |
Why?
|
| Models, Biological | 2 | 2013 | 711 | 0.130 |
Why?
|
| Endothelium | 1 | 2017 | 28 | 0.130 |
Why?
|
| Nerve Tissue Proteins | 1 | 2020 | 382 | 0.130 |
Why?
|
| Air Pollution, Indoor | 1 | 2018 | 50 | 0.130 |
Why?
|
| Adaptive Immunity | 1 | 2017 | 32 | 0.130 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2016 | 18 | 0.130 |
Why?
|
| Mice, Mutant Strains | 2 | 2007 | 85 | 0.130 |
Why?
|
| Nutritional Status | 1 | 2017 | 115 | 0.130 |
Why?
|
| Dogs | 2 | 2016 | 201 | 0.130 |
Why?
|
| Cell Membrane | 1 | 2019 | 400 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2017 | 88 | 0.130 |
Why?
|
| Haplotypes | 4 | 2015 | 197 | 0.130 |
Why?
|
| Cluster Analysis | 1 | 2017 | 206 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 246 | 0.130 |
Why?
|
| Mice, Transgenic | 2 | 2018 | 658 | 0.130 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2016 | 24 | 0.130 |
Why?
|
| Ribonucleoproteins | 1 | 2016 | 31 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 236 | 0.120 |
Why?
|
| Chick Embryo | 1 | 2016 | 77 | 0.120 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 64 | 0.120 |
Why?
|
| Government Regulation | 1 | 2016 | 15 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 1 | 2016 | 75 | 0.120 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 1051 | 0.120 |
Why?
|
| Cytoplasm | 1 | 2016 | 154 | 0.120 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2015 | 25 | 0.120 |
Why?
|
| Incidence | 1 | 2018 | 1054 | 0.120 |
Why?
|
| Lipoxins | 1 | 2015 | 2 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2015 | 10 | 0.120 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2015 | 11 | 0.120 |
Why?
|
| Matrix Metalloproteinases | 1 | 2015 | 49 | 0.110 |
Why?
|
| Maternal Exposure | 1 | 2015 | 56 | 0.110 |
Why?
|
| Dinoprostone | 1 | 2015 | 69 | 0.110 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2015 | 85 | 0.110 |
Why?
|
| Cell Survival | 3 | 2019 | 934 | 0.110 |
Why?
|
| DNA Damage | 2 | 2014 | 358 | 0.110 |
Why?
|
| Blotting, Western | 2 | 2011 | 884 | 0.110 |
Why?
|
| Macrophages | 2 | 2016 | 515 | 0.110 |
Why?
|
| Cell Line | 2 | 2016 | 1416 | 0.110 |
Why?
|
| Kidney | 1 | 2017 | 363 | 0.110 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2014 | 3 | 0.110 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 203 | 0.110 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2014 | 1 | 0.110 |
Why?
|
| Cyclooxygenase 2 | 1 | 2015 | 106 | 0.110 |
Why?
|
| Peptides | 1 | 2017 | 357 | 0.110 |
Why?
|
| Age Factors | 2 | 2021 | 1139 | 0.110 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2014 | 14 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2019 | 1574 | 0.110 |
Why?
|
| Overweight | 1 | 2016 | 248 | 0.110 |
Why?
|
| Interleukin-8 | 1 | 2014 | 74 | 0.110 |
Why?
|
| Genetic Markers | 2 | 2011 | 146 | 0.110 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 2013 | 16 | 0.110 |
Why?
|
| Gene Expression Profiling | 3 | 2012 | 683 | 0.100 |
Why?
|
| Diet | 2 | 2017 | 810 | 0.100 |
Why?
|
| Cilia | 1 | 2013 | 29 | 0.100 |
Why?
|
| Macaca fascicularis | 3 | 2021 | 64 | 0.100 |
Why?
|
| Phosphorylation | 1 | 2016 | 973 | 0.100 |
Why?
|
| Body Mass Index | 2 | 2017 | 916 | 0.100 |
Why?
|
| Histone Deacetylase 1 | 1 | 2013 | 16 | 0.100 |
Why?
|
| Base Sequence | 2 | 2006 | 997 | 0.100 |
Why?
|
| Butyric Acid | 1 | 2013 | 19 | 0.100 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 61 | 0.100 |
Why?
|
| Public Health | 1 | 2017 | 405 | 0.100 |
Why?
|
| Hydroxamic Acids | 1 | 2013 | 34 | 0.100 |
Why?
|
| Acetylation | 1 | 2013 | 108 | 0.100 |
Why?
|
| Child | 5 | 2024 | 3381 | 0.100 |
Why?
|
| Pedigree | 1 | 2013 | 94 | 0.100 |
Why?
|
| Protein Transport | 2 | 2019 | 295 | 0.100 |
Why?
|
| Bezafibrate | 2 | 2003 | 4 | 0.100 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 129 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 2 | 2004 | 454 | 0.100 |
Why?
|
| Genetics, Population | 1 | 2013 | 118 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 2803 | 0.090 |
Why?
|
| Sarin | 2 | 2002 | 7 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 156 | 0.090 |
Why?
|
| Chemical Warfare Agents | 2 | 2002 | 14 | 0.090 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2011 | 1 | 0.090 |
Why?
|
| Interleukin-1beta | 1 | 2012 | 74 | 0.090 |
Why?
|
| Fever | 2 | 2002 | 63 | 0.090 |
Why?
|
| Body Weight | 3 | 2002 | 428 | 0.090 |
Why?
|
| Carcinogens | 2 | 2003 | 126 | 0.090 |
Why?
|
| Indians, North American | 1 | 2014 | 179 | 0.090 |
Why?
|
| Cell Differentiation | 3 | 2011 | 633 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2024 | 1586 | 0.090 |
Why?
|
| Prognosis | 1 | 2014 | 850 | 0.090 |
Why?
|
| Eosinophils | 3 | 2013 | 22 | 0.090 |
Why?
|
| Software | 1 | 2013 | 234 | 0.090 |
Why?
|
| Age Distribution | 1 | 2011 | 249 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 198 | 0.080 |
Why?
|
| Up-Regulation | 3 | 2016 | 534 | 0.080 |
Why?
|
| Genes, p16 | 1 | 2010 | 11 | 0.080 |
Why?
|
| Horses | 2 | 2011 | 28 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2016 | 1420 | 0.080 |
Why?
|
| Alcian Blue | 2 | 2007 | 3 | 0.080 |
Why?
|
| Periodic Acid-Schiff Reaction | 2 | 2007 | 3 | 0.080 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2010 | 12 | 0.080 |
Why?
|
| Nicotine | 2 | 2016 | 290 | 0.080 |
Why?
|
| Myeloid Cells | 1 | 2010 | 31 | 0.080 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2009 | 18 | 0.080 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2009 | 52 | 0.080 |
Why?
|
| Dendritic Cells | 1 | 2010 | 130 | 0.080 |
Why?
|
| Subcellular Fractions | 1 | 2009 | 79 | 0.080 |
Why?
|
| RNA, Catalytic | 1 | 2008 | 5 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 487 | 0.080 |
Why?
|
| Oxidative Stress | 4 | 2017 | 990 | 0.080 |
Why?
|
| Annexin A5 | 1 | 2008 | 27 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 209 | 0.070 |
Why?
|
| Cathepsin D | 1 | 2008 | 17 | 0.070 |
Why?
|
| Gene Frequency | 3 | 2015 | 203 | 0.070 |
Why?
|
| Muscle Cells | 1 | 2008 | 12 | 0.070 |
Why?
|
| Cathepsin B | 1 | 2008 | 35 | 0.070 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2008 | 9 | 0.070 |
Why?
|
| Protein Binding | 1 | 2012 | 1076 | 0.070 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 12 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 301 | 0.070 |
Why?
|
| Autopsy | 1 | 2008 | 46 | 0.070 |
Why?
|
| Hematoxylin | 1 | 2007 | 1 | 0.070 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2007 | 3 | 0.070 |
Why?
|
| Hemagglutinins | 1 | 2007 | 9 | 0.070 |
Why?
|
| Antioxidants | 1 | 2011 | 439 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2007 | 62 | 0.070 |
Why?
|
| Coloring Agents | 1 | 2007 | 56 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2024 | 1516 | 0.070 |
Why?
|
| Cytochromes c | 1 | 2007 | 48 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2007 | 151 | 0.070 |
Why?
|
| Administration, Intranasal | 2 | 2024 | 89 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 1 | 2007 | 207 | 0.060 |
Why?
|
| Sex Factors | 1 | 2010 | 1008 | 0.060 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2006 | 2 | 0.060 |
Why?
|
| Fluorescent Dyes | 1 | 2007 | 182 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2006 | 17 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2006 | 97 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2008 | 297 | 0.060 |
Why?
|
| Southwestern United States | 1 | 2006 | 47 | 0.060 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 58 | 0.060 |
Why?
|
| Eosinophilia | 2 | 2002 | 16 | 0.060 |
Why?
|
| Leukocyte Count | 2 | 2004 | 68 | 0.060 |
Why?
|
| Nucleocapsid Proteins | 1 | 2025 | 12 | 0.060 |
Why?
|
| Viral Core Proteins | 1 | 2025 | 13 | 0.060 |
Why?
|
| Recurrence | 1 | 2006 | 149 | 0.060 |
Why?
|
| Interleukin-4 | 1 | 2005 | 75 | 0.060 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 928 | 0.060 |
Why?
|
| Body Temperature | 2 | 2002 | 35 | 0.060 |
Why?
|
| Fuchs' Endothelial Dystrophy | 1 | 2024 | 2 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 82 | 0.060 |
Why?
|
| Interleukin-12 | 1 | 2004 | 46 | 0.060 |
Why?
|
| Adolescent | 3 | 2024 | 5950 | 0.060 |
Why?
|
| Reference Values | 1 | 2004 | 207 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 4 | 2013 | 686 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 200 | 0.050 |
Why?
|
| Protein Subunits | 1 | 2004 | 93 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 88 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2025 | 158 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2004 | 117 | 0.050 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2003 | 2 | 0.050 |
Why?
|
| Beryllium | 1 | 2003 | 5 | 0.050 |
Why?
|
| Nitrosamines | 1 | 2003 | 11 | 0.050 |
Why?
|
| Ploidies | 1 | 2003 | 7 | 0.050 |
Why?
|
| Young Adult | 3 | 2024 | 4936 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 116 | 0.050 |
Why?
|
| Microscopy, Electron | 1 | 2003 | 209 | 0.050 |
Why?
|
| Nucleoproteins | 1 | 2023 | 15 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 123 | 0.050 |
Why?
|
| Costa Rica | 2 | 2014 | 9 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 602 | 0.050 |
Why?
|
| P-Selectin | 1 | 2002 | 8 | 0.050 |
Why?
|
| Culture Techniques | 1 | 2002 | 26 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 241 | 0.050 |
Why?
|
| Dissection | 1 | 2002 | 12 | 0.050 |
Why?
|
| Caspases | 1 | 2023 | 148 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2002 | 379 | 0.050 |
Why?
|
| Alpha-Globulins | 1 | 2002 | 4 | 0.050 |
Why?
|
| Cyclic AMP | 1 | 2003 | 135 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 295 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 1058 | 0.050 |
Why?
|
| Alleles | 2 | 2017 | 352 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2002 | 44 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 99 | 0.050 |
Why?
|
| Hydrocarbons | 1 | 2002 | 4 | 0.050 |
Why?
|
| Nitrogen Oxides | 1 | 2002 | 7 | 0.050 |
Why?
|
| Transfection | 1 | 2003 | 526 | 0.050 |
Why?
|
| Larynx | 1 | 2002 | 8 | 0.050 |
Why?
|
| Hypoxanthines | 1 | 2021 | 3 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2002 | 27 | 0.050 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 2021 | 7 | 0.050 |
Why?
|
| Endotoxins | 1 | 2002 | 18 | 0.050 |
Why?
|
| Ozone | 1 | 2002 | 26 | 0.050 |
Why?
|
| Bronchitis | 1 | 2001 | 5 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2008 | 979 | 0.050 |
Why?
|
| Pigmentation | 1 | 2002 | 27 | 0.050 |
Why?
|
| Molecular Sequence Data | 1 | 2004 | 1559 | 0.050 |
Why?
|
| Arachidonic Acid | 1 | 2001 | 35 | 0.050 |
Why?
|
| Pituitary-Adrenal System | 1 | 2001 | 41 | 0.040 |
Why?
|
| Heterozygote | 1 | 2001 | 107 | 0.040 |
Why?
|
| Equipment Design | 1 | 2002 | 143 | 0.040 |
Why?
|
| Persian Gulf Syndrome | 1 | 2001 | 4 | 0.040 |
Why?
|
| Receptors, Cholinergic | 1 | 2001 | 28 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 48 | 0.040 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2001 | 55 | 0.040 |
Why?
|
| Papio papio | 1 | 2021 | 1 | 0.040 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2003 | 188 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2001 | 92 | 0.040 |
Why?
|
| Vehicle Emissions | 1 | 2001 | 22 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2001 | 26 | 0.040 |
Why?
|
| Spleen | 1 | 2001 | 199 | 0.040 |
Why?
|
| Trans-Activators | 1 | 2002 | 190 | 0.040 |
Why?
|
| Respiratory System | 1 | 2021 | 31 | 0.040 |
Why?
|
| Particle Size | 1 | 2002 | 267 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 2000 | 54 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2001 | 77 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2020 | 13 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2000 | 27 | 0.040 |
Why?
|
| Retinoids | 1 | 2000 | 25 | 0.040 |
Why?
|
| Kinetics | 1 | 2002 | 698 | 0.040 |
Why?
|
| DNA | 1 | 2003 | 594 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2015 | 452 | 0.040 |
Why?
|
| Eating | 1 | 2001 | 164 | 0.040 |
Why?
|
| Stress, Physiological | 1 | 2001 | 170 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 599 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2018 | 2485 | 0.040 |
Why?
|
| Benzo(a)pyrene | 1 | 2001 | 128 | 0.040 |
Why?
|
| Animals, Newborn | 1 | 2021 | 350 | 0.040 |
Why?
|
| Carbon | 1 | 2001 | 127 | 0.040 |
Why?
|
| Biomedical Research | 2 | 2017 | 467 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2001 | 243 | 0.040 |
Why?
|
| Protein Engineering | 1 | 2019 | 47 | 0.040 |
Why?
|
| Cell Movement | 1 | 2003 | 640 | 0.040 |
Why?
|
| Motor Activity | 1 | 2001 | 438 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 557 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 353 | 0.040 |
Why?
|
| Household Products | 1 | 2018 | 2 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2018 | 362 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 114 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2016 | 5 | 0.030 |
Why?
|
| Aging | 1 | 2022 | 764 | 0.030 |
Why?
|
| beta-Galactosidase | 1 | 2016 | 37 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2016 | 32 | 0.030 |
Why?
|
| Animal Experimentation | 1 | 2016 | 3 | 0.030 |
Why?
|
| Mucociliary Clearance | 1 | 2016 | 5 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2016 | 28 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2019 | 518 | 0.030 |
Why?
|
| Keratins | 1 | 2015 | 25 | 0.030 |
Why?
|
| Mecamylamine | 1 | 2015 | 21 | 0.030 |
Why?
|
| Thiobarbituric Acid Reactive Substances | 1 | 2015 | 14 | 0.030 |
Why?
|
| Phospholipases A2, Secretory | 1 | 2015 | 2 | 0.030 |
Why?
|
| Gene Knock-In Techniques | 1 | 2015 | 15 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2015 | 62 | 0.030 |
Why?
|
| Immunoglobulin E | 2 | 2008 | 59 | 0.030 |
Why?
|
| Pregnancy | 2 | 2015 | 1737 | 0.030 |
Why?
|
| Integrin alpha Chains | 1 | 2014 | 3 | 0.030 |
Why?
|
| Fibrinolysin | 1 | 2014 | 9 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 733 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 183 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 289 | 0.030 |
Why?
|
| Mutation | 1 | 2019 | 1169 | 0.030 |
Why?
|
| Phenylbutyrates | 1 | 2013 | 5 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2008 | 253 | 0.030 |
Why?
|
| Leukocytes | 1 | 2014 | 79 | 0.030 |
Why?
|
| Sirtuin 1 | 1 | 2013 | 33 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 158 | 0.030 |
Why?
|
| Cytosol | 1 | 2013 | 98 | 0.030 |
Why?
|
| Aldehydes | 1 | 2013 | 69 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 180 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 196 | 0.020 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 85 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 87 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2013 | 118 | 0.020 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 89 | 0.020 |
Why?
|
| Genome, Human | 1 | 2013 | 143 | 0.020 |
Why?
|
| DNA Ligases | 1 | 2011 | 13 | 0.020 |
Why?
|
| Nasal Obstruction | 1 | 2011 | 2 | 0.020 |
Why?
|
| Gelatinases | 1 | 2011 | 8 | 0.020 |
Why?
|
| Enzyme Precursors | 1 | 2011 | 14 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2011 | 51 | 0.020 |
Why?
|
| Clone Cells | 1 | 2011 | 50 | 0.020 |
Why?
|
| Culture Media, Serum-Free | 1 | 2011 | 44 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 436 | 0.020 |
Why?
|
| Culture Media | 1 | 2011 | 96 | 0.020 |
Why?
|
| Azacitidine | 1 | 2011 | 22 | 0.020 |
Why?
|
| International Cooperation | 1 | 2011 | 51 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 56 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 78 | 0.020 |
Why?
|
| Vegetables | 1 | 2011 | 145 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 324 | 0.020 |
Why?
|
| Pyridines | 1 | 2011 | 134 | 0.020 |
Why?
|
| Fruit | 1 | 2011 | 178 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 508 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2011 | 339 | 0.020 |
Why?
|
| Ambrosia | 1 | 2008 | 2 | 0.020 |
Why?
|
| Leukotriene C4 | 1 | 2008 | 6 | 0.020 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 1 | 2008 | 3 | 0.020 |
Why?
|
| Caspase 8 | 1 | 2008 | 32 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 246 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2006 | 124 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2008 | 290 | 0.010 |
Why?
|
| Interleukin-12 Subunit p40 | 1 | 2004 | 4 | 0.010 |
Why?
|
| Bronchiolitis, Viral | 1 | 2004 | 2 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 2004 | 11 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 2004 | 21 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2004 | 55 | 0.010 |
Why?
|
| Brain | 2 | 2002 | 1452 | 0.010 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2003 | 6 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 4 | 1 | 2003 | 9 | 0.010 |
Why?
|
| Viral Load | 1 | 2004 | 344 | 0.010 |
Why?
|
| Receptors, Muscarinic | 1 | 2002 | 17 | 0.010 |
Why?
|
| Turpentine | 1 | 2002 | 1 | 0.010 |
Why?
|
| Acetylcholinesterase | 1 | 2002 | 55 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2002 | 39 | 0.010 |
Why?
|
| Bronchoconstrictor Agents | 1 | 2001 | 1 | 0.010 |
Why?
|
| Methacholine Chloride | 1 | 2001 | 2 | 0.010 |
Why?
|
| Bronchial Provocation Tests | 1 | 2001 | 5 | 0.010 |
Why?
|
| Solvents | 1 | 2002 | 109 | 0.010 |
Why?
|
| Chemokine CXCL2 | 1 | 2001 | 12 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 2001 | 47 | 0.010 |
Why?
|
| Autoradiography | 1 | 2001 | 35 | 0.010 |
Why?
|
| Peroxidase | 1 | 2001 | 57 | 0.010 |
Why?
|
| Airway Resistance | 1 | 2001 | 6 | 0.010 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2001 | 23 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 2001 | 30 | 0.010 |
Why?
|
| Immunization Schedule | 1 | 2001 | 9 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 57 | 0.010 |
Why?
|
| Immune System | 1 | 2001 | 40 | 0.010 |
Why?
|
| Immunization | 1 | 2001 | 93 | 0.010 |
Why?
|
| Biological Availability | 1 | 2001 | 115 | 0.010 |
Why?
|
| Models, Animal | 1 | 2001 | 149 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 230 | 0.010 |
Why?
|
| Naphthalenes | 1 | 2000 | 38 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 244 | 0.010 |
Why?
|
| Head and Neck Neoplasms | 1 | 2000 | 81 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 457 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2000 | 506 | 0.010 |
Why?
|
| Liver | 1 | 2002 | 503 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2000 | 187 | 0.010 |
Why?
|